For twenty-six years the number sat still. NICE would judge a new medicine cost-effective if it delivered a year of healthy life for somewhere between twenty and thirty thousand pounds. Committees built careers around that range. Manufacturers built launch strategies around it. Patients waited on the outcome of it without ever knowing the figure existed. This spring the range moved, to twenty-five and thirty-five thousand pounds, the first change of its kind since the threshold was set. It sounds like an accounting adjustment. It is closer to a wager on a theory that has circulated in health policy circles for years: that the choice between cheaper medicines and better ones is a false one, and that governments can have both if they simply get the pricing mechanism right.

The theory has an obvious appeal. Pharmaceutical companies have spent a decade launching incremental variants of existing blockbusters while original research into diseases with no safe financial return withers. Much of that behaviour follows the money rather than the medicine, because a modest reformulation with predictable margins will always look safer to a board than a billion pounds staked on an unproven target. The fix, in principle, is to make the reward track the benefit. Pay properly for medicines that genuinely extend or improve life. Pay less, or nothing at all, for the ones that do not. NICE's quality-adjusted life year has been doing a version of this since the institute was founded. The government's decision to increase the threshold for what constitutes excellent value this year was made on the specific grounds that the previous range was impeding the necessary investment in the UK life sciences sector.

Whether that logic survives contact with implementation is the more interesting question, and it is one the NHS cannot avoid answering. Raising the threshold without credible proof of its own effects runs the risk of transforming a scientific procedure into a political ploy, as health economists have already noted, since every pound spent to clear the new bar for a marginal medication is a pound not used on services that have already been shown to be effective. NICE itself expects three to five additional medicines a year to clear the revised bar. Nobody has yet costed what falls out of the budget to pay for them. That is not a small omission. It is the entire mechanism by which value-based pricing is supposed to keep its promise, and at present it is running on faith rather than arithmetic.

Alongside the threshold change sits the Voluntary Scheme for Branded Medicines Pricing, Access and Growth, the rebate arrangement under which drug companies return a share of NHS sales revenue above an agreed growth cap. It was meant to be the other lever in the same alignment project, restraining runaway spend on medicines while leaving headroom for genuine innovation. Instead it has become the site of the row that nearly derailed the whole strategy. Rebate rates climbed past twenty per cent, industry accused ministers of extracting an unsustainable toll, and talks to reform the scheme collapsed without agreement. A new cap agreed as part of the wider pricing arrangement with Washington brings some relief from 2026, but the underlying dispute about who absorbs the cost of a growing medicines bill has not gone away. It has simply been rescheduled.

What this leaves the NHS holding is not a solved problem but a working demonstration of how hard the solved version actually is. Aligning profit with clinical value requires a regulator willing to say no to politically inconvenient answers, a Treasury willing to fund the yes decisions without raiding services elsewhere, and an industry willing to accept that alignment cuts both ways. Britain has, arguably, the most developed apparatus in the world for attempting this. It is also discovering, in the same year it recalibrated that apparatus, that having the right mechanism is not the same as having resolved who pays and who loses when it is used. For NHS finance directors and life sciences investors watching the same numbers, that distinction is not academic. It will show up in next year's budget, and in which medicines actually reach patients.